Prosecution Insights
Last updated: August 16, 2026

Momenta Pharmaceuticals Inc.

7 pending office actions • 4 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
5
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (43%)
4
Medium (57%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other2 (29%)
Double-patenting + other4 (57%)
Multi-statute (no §101)1 (14%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DAHLE, CHUN WU 2 49.8% +51.4%
JOHANSEN, PETER N. 1 58.9% +24.3%
HADDAD, MAHER M 1 50.5% +53.9%
LEONARD, ARTHUR S 1 50.9% +50.5%
KIM, YUNSOO 1 65.8% +34.8%
RAGHU, GANAPATHIRAM 1 73.6% +26.4%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18218996 Sialylated Glycoproteins HADDAD, MAHER M 36d overdue
18217401 Sialylated Glycoproteins LEONARD, ARTHUR S 4d overdue
17909282 METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN RAGHU, GANAPATHIRAM 23d

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18022069 SIALYLATED GLYCOPROTEINS KIM, YUNSOO 52d overdue
18218996 Sialylated Glycoproteins HADDAD, MAHER M 36d overdue
18217401 Sialylated Glycoproteins LEONARD, ARTHUR S 4d overdue
17909282 METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN RAGHU, GANAPATHIRAM 23d
18520171 ENGINEERED Fc CONSTRUCTS DAHLE, CHUN WU
18286455 COMPOSITIONS AND METHODS FOR TREATING PEDIATRIC MYASTHENIA GRAVIS JOHANSEN, PETER N.
18351827 FcRn Antibodies and Methods of Use Thereof DAHLE, CHUN WU

Top Art Units

Art UnitApps
1641 4
1644 1
1631 1
1652 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18520171 ENGINEERED Fc CONSTRUCTS DAHLE, CHUN WU 1641 §102DP Non-Final OA Pending Nov 27, 2023
18286455 COMPOSITIONS AND METHODS FOR TREATING PEDIATRIC MYASTHENIA GRAVIS JOHANSEN, PETER N. 1644 §103§112DP Non-Final OA Pending Oct 11, 2023
18351827 FcRn Antibodies and Methods of Use Thereof DAHLE, CHUN WU 1641 §112DP Non-Final OA Pending Jul 13, 2023
18218996 Sialylated Glycoproteins HADDAD, MAHER M 1641 §101§112Other Non-Final OA 36d overdue Pending Jul 06, 2023
18217401 Sialylated Glycoproteins LEONARD, ARTHUR S 1631 §101§103§112 Non-Final OA 4d overdue Pending Jun 30, 2023
18022069 SIALYLATED GLYCOPROTEINS KIM, YUNSOO 1641 §103§112DP Final Rejection 52d overdue Pending Feb 17, 2023
17909282 METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN RAGHU, GANAPATHIRAM 1652 §102§103§112Other Non-Final OA 23d Pending Sep 02, 2022

Managing Momenta Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month